After the Food and Drug Administration (FDA) approved docetaxel for metastatic castration-resistant prostate cancer (mCRPC) 
Radium223-Before or After Docetaxel?
Radium223 prolonged overall survival in the entire population, both docetaxel-pretreated and docetaxel-naïve patients in ALSYMPCA.
However, the secondary endpoint of symptomatic skeletal-related events (sSRE) showed a majority of benefit conferred to the docetaxel-pretreated subgroup. 2 The median time to sSRE was 13.5 months in the Radium223 group compared with 7.8 months for placebo in docetaxel-pretreated patients (p=0.00087), whereas the median time to sSRE was 17 months for Radium223 patients and 19.5 months for placebo in docetaxel-naïve patients (p=0.12). While this is a subgroup analysis, warranting cautious interpretation, it is plausible that docetaxel-pretreated patients with bone pain represent an enriched, more aggressive subgroup in which bone targeting therapy may yield a greater impact.
However, docetaxel-pretreated patients also have modestly higher rates of hematologic toxicity according to a subgroup analysis of the ALSYMPCA data set. 
Should We Use Radium223 Earlier in the Disease State or with Lower Volume Disease?
Given that median overall survival can be >30 months based on predocetaxel studies such as PREVAIL, 5 reduced myeloid reserve could affect future chemotherapy administration. Also, the concern for secondary malignancy risk is greater when applying Radium223 earlier in the disease process.
Limited data derived from ALSYMPCA suggest that docetaxel can be given in full doses without excess toxicity after Radium223 administration 6 ; however, there are no data about a second course of docetaxel or administration of cabazitaxel in such patients. The follow-up data from ALSYMPCA have failed to reveal excess secondary malignancy, but are still relatively short term, with a median follow-up of less than 1 year. 7 More data related to longterm consequences would be helpful before moving Radium223 forward into patients with longer life expectancies. Furthermore, the subgroup analyses from ALSYMPCA, taken as a whole, point toward greater benefit in patients with higher disease burden, recognizing the serious limitations of subgroup analyses. Specifically, lower volume disease (less than 6 bone metastases) and lower alkaline phosphatase (<220) trended toward less benefit from Radium223. 1 Lower numbers of events could explain the discrepancies, but for now these factors warrant consideration when evaluating whether a patient will benefit from Radium223.
Conclusion
With multiple available life-extending therapies for mCRPC, many with palliative benefits in addition to survival benefits, questions persist regarding optimal sequencing. We know that the biology of prostate cancer changes 
